Advances in Metabolic Reprogramming and Immune Regulatory Mechanisms in Lung Cancer
Oncology Research · 2026 · 34 (4) · 1-10
DOI: 10.32604/or.2026.076176 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Research, 2026. Verfasst von Xiaomeng Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Intervention, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, No. 127, Dongming Road, Jinsh…. Hauptthemen laut MEDLINE: Metabolic Reprogramming, Lung Neoplasms. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory Intervention, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, No. 127, Dongming Road, Jinshui District, Zhengzhou, China.
- Department of Basic Medicine Science, North Henan Medical University, Xinxiang, China.
Zitieren
APA
Li, X., Li, X., Wu, H., & Li, R. (2026). Advances in Metabolic Reprogramming and Immune Regulatory Mechanisms in Lung Cancer. Oncology Research, 34(4), 1-10. https://doi.org/10.32604/or.2026.076176
Vancouver
Li X, Li X, Wu H, Li R. Advances in Metabolic Reprogramming and Immune Regulatory Mechanisms in Lung Cancer. Oncology Research. 2026;34(4):1-10. doi:10.32604/or.2026.076176
BibTeX
@article{Li2026,
author = {Li, Xiaomeng and Li, Xuejiao and Wu, Hongbo and Li, Rui},
title = {Advances in Metabolic Reprogramming and Immune Regulatory Mechanisms in Lung Cancer},
journal = {Oncology Research},
year = {2026},
volume = {34},
number = {4},
pages = {1--10},
doi = {10.32604/or.2026.076176}
}
EUVIMED